Novartis AG (NVS) Stock

NYSE
HealthcareDrug Manufacturers - General Website

NVS has an Alpha Score of 50 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 21 members of Congress disclosed 81 trades in NVS since 2014: 42 purchases and 38 sales, most recently Kevin Hern (sale, Aug 27, 2026). 6 of the hedge funds AlphaScala tracks reported NVS in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Citadel's at $230.06M. Its trailing P/E ratio is 29.1 and its net margin 17.5% (key statistics as of Nov 13, 2026).

$150.47
-0.50%
Last price
Source: Finnhub
Alpha Score
50
Weak

What is NVS's Alpha Score?

How it works →

Alpha Score of 50 reflects moderate overall profile with moderate momentum, moderate value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
65
Moderate
Value
53
Weak
Quality
48
Weak

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Novartis AG (NVS)?

Members
21
Disclosed trades
81
Purchases
42
Sales
38

Most recent: Kevin Hern (sale, Aug 27, 2026); records start Jun 12, 2014.

PoliticianTrade dateTypeAmount
Kevin Hern
R-OK · House
2026-08-27sale$15k – $50k
Alan Armstrong
R-OK · Senate
2026-03-31purchase$1k – $15k
Alan Armstrong
R-OK · Senate
2026-03-30purchase$15k – $50k
Lisa McClain
R-MI · House
2025-10-31sale$1k – $15k
Lisa McClain
R-MI · House
2025-10-30sale$1k – $15k
Lisa McClain
R-MI · House
2025-10-30purchase$1k – $15k
Lisa McClain
R-MI · House
2025-09-25partial sale$1k – $15k
Lisa McClain
R-MI · House
2025-09-11purchase$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded NVS, with filing lags →

Which hedge funds own NVS?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Citadel
Ken Griffin
1.61M$230.06M+403%
Renaissance Technologies
Jim Simons (founder)
662K$94.33M-16%
Millennium Management
Israel Englander
503K$71.74M-34%
Point72
Steve Cohen
262K$37.37M+147%
Maverick Capital
Lee Ainslie
19K$2.66M-33%
D.E. Shaw
David Shaw
18K$2.53MNEW

13F holdings as of Sep 30, 2026

Explore all tracked funds →

What are NVS's key statistics?

P/E Ratio
29.13
EPS (TTM)
5.23
Dividend Yield
3.72%
Beta
1.34
Net Margin
17.50%
ROE
24.55%
Debt / Equity
0.77
52W High
$135.22
52W Low
$99.45

Key statistics as of Nov 13, 2026

How does NVS's valuation compare with the Healthcare sector?

MetricNVSHealthcare medianCompanies in median
P/E ratio29.128.8145
Net margin17.50%3.62%218
Return on equity24.55%3.50%249
Dividend yield (payers)3.72%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 21, 2026). P/E excludes loss-making companies.

NVS price chart

Powered by TradingView

What does Novartis AG do?

Novartis AG Sponsored ADR represents the American Depositary Receipts of Novartis AG, a Swiss-based innovative medicines company headquartered in Basel. This ADR enables U.S. investors convenient access to Novartis AG shares, facilitating liquidity and exposure to global pharmaceutical innovation. Novartis AG focuses on researching, developing, producing, distributing, and commercializing advanced treatments across key therapeutic areas, including oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases, and respiratory conditions. Its portfolio features prominent products such as Entresto and Leqvio in cardiovascular; Cosentyx, Xolair, and Ilaris in immunology; Kesimpta, Zolgensma, and Mayzent in neuroscience; and oncology offerings like Kisqali, Pluvicto, Lutathera, Kymriah, and Scemblix. Additionally, established brands like Lucentis and Sandostatin support ongoing patient care. Operating as a single global segment post its generics spin-off, Novartis AG delivers medicines worldwide, emphasizing research-driven solutions that address serious diseases and enhance healthcare accessibility. Founded in 1996, the company maintains a significant presence in the healthcare sector through its broad therapeutic expertise.

Employees
75,883
Market Cap
$242.99B
Ask about NVSAI research agent